Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Por um escritor misterioso
Descrição
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives
Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy
Imaging of Response to Radiosurgery and Immunotherapy in Brain Metastases: Quo Vadis?
Frontiers Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
Figure 1 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma
Full article: Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma
Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases - Cancer Therapy Advisor
Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis - ScienceDirect
Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. - Document - Gale OneFile: Health and Medicine
Immunotherapy Drugs Shrink Brain Metastases from Melanoma - NCI
de
por adulto (o preço varia de acordo com o tamanho do grupo)
